Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan

Losses are narrowing, but cash burn and pipeline risks remain high for Coherus Oncology.

What the company is saying

Coherus Oncology, Inc. (NASDAQ:CHRS) is emphasizing a strategic shift to focus its tagmokitug program on esophageal cancer, citing this as its 'best-in-disease' opportunity. CEO Denny Lanfear frames the company's recent operational changes—including the wind-down of the Transition Services Agreement and completion of the toripalimab process transfer—as steps to 'right-size' the organization for financial benefit. The company claims that these actions will lower core cash burn by $6 million to $7 million per quarter over the next two quarters, reducing the LOQTORZI revenue required to cover core burn to $25 million to $30 million, down from $30 million to $35 million. Management highlights LOQTORZI’s unique FDA-approved status for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma and its preferred status in NCCN guidelines. The narrative is confident, with forward-looking statements about achieving financial self-sufficiency and expedited clinical development, but also acknowledges the need for FDA alignment and further clinical progress. CFO Bryan McMichael attributes improved cost structure to reduced headcount, lower infrastructure, and the completed exit from the biosimilar business.

What the data suggests

LOQTORZI revenue for Q3 2026 was $14.0 million, up 25% from $11.2 million in Q3 2025 and up 3% from $13.6 million in Q2 2026. Net revenue from continuing operations was $14.3 million for Q3 2026 and $40.9 million for the nine months ended September 30, 2026, compared to $11.6 million and $29.4 million for the same periods in 2025. Cost of goods sold rose to $4.1 million in Q3 2026 from $3.7 million in Q3 2025. R&D expenses fell to $22.6 million in Q3 2026 from $27.3 million in Q3 2025, and SG&A expenses dropped to $21.2 million from $24.9 million. Net loss from continuing operations narrowed to $38.9 million ($0.25 per share) in Q3 2026 from $44.5 million ($0.38 per share) in Q3 2025. For the nine months, net loss was $109.2 million ($0.73 per share), down from $136.8 million ($1.18 per share) in 2025. Non-GAAP net loss for Q3 2026 was $31.2 million ($0.20 per share), versus $38.9 million ($0.33 per share) in Q3 2025. Cash, cash equivalents, and marketable securities fell to $83.6 million at September 30, 2026, from $172.1 million at year-end 2025. TSA-related collections to be applied to payables were $19.6 million at September 30, 2026, down from $65.1 million at year-end 2025. Clinical data for tagmokitug in second-line ESCC/EAC showed a confirmed ORR of 33.3% and a CBR of 55.6% among 13 evaluable patients, with median progression-free survival of 5.5 months. The company’s financial trajectory is improving, with narrowing losses and lower expenses, but cash reserves are declining and LOQTORZI revenue remains well below the new $25 million–$30 million quarterly threshold needed to cover core burn.

Analysis

The announcement presents a balanced tone, with detailed financial disclosures showing narrowing losses and revenue growth, but also significant ongoing net losses and declining cash reserves. While the company highlights operational progress (e.g., LOQTORZI revenue growth, clinical trial milestones), many key claims are forward-looking, such as expectations for reduced cash burn, planned clinical studies, and anticipated regulatory alignment. The narrative emphasizes strategic prioritization and future benefits, but the majority of pipeline advances (e.g., new studies, data readouts) are not yet realized and will take at least several quarters to materialize. There is no evidence of a large new capital outlay in this update, and the cost reduction efforts are incremental rather than transformative. The gap between narrative and evidence is moderate: realized financial improvements are incremental, while much of the operational optimism is contingent on future clinical and regulatory outcomes.

Risk flags

• ●Cash reserves declined sharply from $172.1 million at December 31, 2025, to $83.6 million at September 30, 2026, raising liquidity concerns if revenue growth does not accelerate or if cost reductions are not fully realized.
• ●LOQTORZI revenue, while growing, remains well below the $25 million–$30 million per quarter needed to cover core burn, indicating a continued reliance on external funding or further cost cuts unless sales ramp up significantly.
• ●The company’s clinical pipeline is heavily dependent on successful regulatory alignment and trial outcomes for tagmokitug and casdozokitug, with key milestones still pending and subject to clinical and regulatory risk.
• ●The transition away from the biosimilar business and organizational right-sizing may disrupt operations or delay pipeline progress if not managed carefully, especially given ongoing clinical trial commitments.
• ●Forward-looking claims about financial self-sufficiency and expedited development are not yet supported by realized revenue or regulatory achievements, increasing the risk of a gap between expectations and delivery.

Bottom line

Coherus Oncology’s Q3 2026 update shows progress in narrowing losses and cutting expenses, but the company remains deeply unprofitable and is burning through cash at a rapid pace. LOQTORZI revenue is increasing but is still far below the level required to cover core operating costs, even after planned reductions. The company’s pipeline offers potential, with promising early clinical data for tagmokitug and ongoing studies for casdozokitug, but these programs are still in early or mid-stage development and face substantial execution and regulatory hurdles. Cash reserves have nearly halved in nine months, and the company’s path to financial self-sufficiency depends on both accelerating LOQTORZI sales and successful, timely clinical development. Investors should focus on whether LOQTORZI revenue can approach the new $25 million–$30 million quarterly target and whether near-term clinical milestones are achieved without further erosion of the cash position. The most important takeaway is that while operational efficiency is improving, the company’s financial runway and commercial traction remain significant risks.

Announcement summary

(NASDAQ:CHRS) Coherus Oncology, Inc. reported financial results for the third quarter of 2026 and provided an update on recent business highlights. The company is strategically prioritizing esophageal cancer as its primary focus for tagmokitug, alongside the wind-down of the Transition Services Agreement and completion of the toripalimab process transfer. Coherus expects to lower its core cash burn by $6 million to $7 million per quarter over the next two quarters, reducing the quarterly LOQTORZI revenues required to cover core burn to $25 million to $30 million, down from the previous guidance of $30 million to $35 million. LOQTORZI revenue for Q3 2026 was $14.0 million, representing a 25% increase over $11.2 million in Q3 2025 and a 3% increase over $13.6 million in Q2 2026. LOQTORZI remains the only FDA-approved and available treatment in the U.S. for recurrent, locally advanced, or metastatic nasopharyngeal carcinoma (NPC), and is the only preferred Category 1 first-line treatment option recommended in combination with cisplatin and gemcitabine, as well as the only preferred subsequent-line treatment recommended by the National Comprehensive Cancer Network (NCCN). Tagmokitug is being evaluated in the TREGCHECK Phase 1b/2a clinical program in combination with toripalimab, with and without chemotherapy, with a near-term focus on esophageal cancer. The company will continue ongoing first-line and second-line ESCC and EAC indications and pursue regulatory alignment on an expedited development path, initially focused on second-line esophageal cancer. In the second-line ESCC/EAC cohort, 22 patients were treated and 13 were evaluable, with a confirmed overall response rate (ORR) of 33.3% and a clinical benefit rate (CBR) of 55.6%. In the 700 mg dose sub-group, the CBR was 55.6% and the confirmed ORR was 33.3%. Median progression-free survival was 5.5 months as of October 14, 2026. Coherus plans to initiate a new study evaluating tagmokitug in combination with toripalimab in second-line esophageal cancer and intends to align with the FDA on the design and proposed 700 mg dose. The company also plans to proceed with a Phase 1b clinical study evaluating tagmokitug in combination with pasritamig in metastatic castration-resistant prostate cancer (mCRPC), expected to initiate in fall 2026. Casdozokitug is being evaluated in a Phase 2 study in first-line unresectable hepatocellular carcinoma (uHCC), with enrollment complete and the first data readout expected in the first half of 2027. Net revenue from continuing operations was $14.3 million for Q3 2026 and $11.6 million for Q3 2025, and $40.9 million for the nine months ended September 30, 2026, compared to $29.4 million for the same period in 2025. Cost of goods sold was $4.1 million for Q3 2026 and $3.7 million for Q3 2025, and $12.1 million for the nine months ended September 30, 2026, compared to $9.8 million for the same period in 2025. Research and development expenses were $22.6 million for Q3 2026 and $27.3 million for Q3 2025, and $65.6 million for the nine months ended September 30, 2026, compared to $77.9 million for the same period in 2025. Selling, general and administrative expenses were $21.2 million for Q3 2026 and $24.9 million for Q3 2025, and $65.3 million for the nine months ended September 30, 2026, compared to $77.0 million for the same period in 2025. Net loss from continuing operations for Q3 2026 was $38.9 million, or $(0.25) per share diluted, compared to $44.5 million, or $(0.38) per share diluted, for Q3 2025. Net loss for the nine months ended September 2026 was $109.2 million, or $(0.73) per share diluted, compared to $136.8 million, or $(1.18) per share diluted, for the same period in 2025. Non-GAAP net loss from continuing operations for Q3 2026 was $31.2 million, or $(0.20) per share diluted, compared to $38.9 million, or $(0.33) per share for Q3 2025. Non-GAAP net loss for the nine months ended September 2026 was $95.3 million, or $(0.64) per share diluted, compared to $118.8 million, or $(1.02) per share for the same period in 2025. Cash, cash equivalents, and marketable securities totaled $83.6 million as of September 30, 2026, compared to $172.1 million as of December 31, 2025. TSA-related collections to be applied to associated payables and accrued liabilities totaled $19.6 million as of September 30, 2026, and $65.1 million as of December 31, 2025. The company will hold a conference call on November 9, 2026, at 5:00 p.m. Eastern Standard Time.

Disagree with this article?